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Severe Left Ventricular DysfunctionABSTRACTThe highest-risk patients with heart failure with reduced ejection fraction are those with ischemic cardiomyopathy and
severe left ventricular systolic dysfunction (ejection fraction #35%). The cornerstone of treatment is guideline-driven
medical therapy for all patients and implantable device therapy for appropriately selected patients. Surgical revascu-
larization offers the potential for improved survival and quality of life, particularly in patients with more extensive
multivessel disease and the greatest degree of left ventricular systolic dysfunction and remodeling. These are also
the patients at greatest short-term risk of mortality with coronary artery bypass graft surgery. The short-term risks
of surgery need to be balanced against the potential for long-term beneﬁt. This review discusses the evolving data on
the role of surgical revascularization, surgical ventricular reconstruction, and mitral valve surgery in this high-risk
patient population. (J Am Coll Cardiol 2015;65:615–24) © 2015 by the American College of Cardiology Foundation.T he estimated population prevalence of heartfailure in the developed world is 1% to 2%(1). In the United States, an estimated 5.1
million adults are living with heart failure (2) and at
least one-half have heart failure with reduced ejec-
tion fraction (HF-REF) (3). The most common etiology
of HF-REF in the developed world is ischemic heart
disease, which is associated with >60% of diagnoses
(4). Patients with ischemic causes of left ventricular
(LV) systolic dysfunction have signiﬁcantly higher
mortality rates than those with nonischemic etiol-
ogies (5). This more aggressive course represents the
convergence of ischemia, myocardial ﬁbrosis, and
endothelial dysfunction, which are superimposed on
the inherent progressive nature of LV dysfunction,
often with associated comorbidities, such as diabetes,
which accelerate the adverse clinical trajectory.
The cornerstone of treatment for patients with
HF-REF remains guideline-directed medical therapy
(GDMT) (3,6), which is associated with signiﬁcant
improvement in survival and quality of life. The most
commonly considered surgical interventions for pa-
tients with HF-REF are coronary artery bypass graft
surgery (CABG), at times paired with surgical ven-
tricular reconstruction (SVR), and surgery for mitral
valve regurgitation. Percutaneous coronary inter-
vention (PCI) has been less well studied. Other pro-
cedures with the potential to prolong life in patients
with HF-REF include insertion of implantable
cardioverter-deﬁbrillators, cardiac resynchronization
therapy (CRT) among those with left bundle branch
block, and orthotopic heart transplantation and LV
assist devices in highly selected patients with
advanced disease (3). In patients with HF-REF whohave coronary artery disease (CAD), an essential
question is whether ﬂow-limiting coronary stenosis
should be treated with CABG. We summarize
observational studies, clinical trial data, and current
thinking on patient selection for revascularization
in severe LV systolic dysfunction.SURGICAL REVASCULARIZATION:
OBSERVATIONAL REPORTS
Until the STICH (Surgical Treatment for Ischemic
Heart Failure) trial, data supporting the role of sur-
gical revascularization for patients with HF-REF
were primarily observational and often drawn from
only a single institution. These studies comparing
survival in patients treated surgically versus medi-
cally suggested uniformly that CABG enhances sur-
vival in patients with HF-REF and CAD (7–14).
Reductions in mortality with surgery compared with
medical therapy ranged from 10% to >50%. Howev-
er, most of these studies either date from the 1960s
and 1970s, before the advent of beta-blockers and
inhibitors of the renin-angiotensin-aldosterone sys-
tem, or fail to provide sufﬁcient detail to determine
if medical management would be optimal by current
standards.SURGICAL REVASCULARIZATION:
CLINICAL TRIALS IN CHRONIC STABLE ANGINA
Findings from early trials comparing medical therapy
with CABG for the treatment of stable angina can only
be loosely applied to the care of patients with HF-REF
AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery
bypass graft
CAD = coronary artery disease
CRT = cardiac
resynchronization therapy
EF = ejection fraction
GDMT = guideline-directed
medical therapy
HF-REF = heart failure with
reduced ejection fraction
LV = left ventricular
LVEF = left ventricular
ejection fraction
MR = mitral regurgitation
NHLBI = National Heart, Lung,
and Blood Institute
PCI = percutaneous
coronary intervention
SVR = surgical ventricular
reconstruction
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617in the current era, because both surgical techniques
and medical therapy have signiﬁcantly improved.
Arterial grafts were rarely used, and medical therapy
largely consisted of only nitrates (typically isosorbide
dinitrate) and inconsistent use of beta-blockers like
propranolol; the medical therapy arms were neither
uniform nor standardized (15–20). In addition, pa-
tients with severe LV dysfunction were largely
excluded. The European Surgery Study (16,19)
enrolled only patients with left ventricular ejection
fraction (LVEF) $50%. In the Veterans Administration
Cooperative Study (15,18), 26% of patients had ejec-
tion fraction (EF) <45%, but none were considered to
have severe LV dysfunction. CASS, the National
Heart, Lung, and Blood Institute (NHLBI) Coronary
Artery Surgery Study (17), excluded patients with
LVEF <35% and/or in New York Heart Association
functional classes III to IV. Only 160 patients enrolled
in CASS had mild to moderate LV dysfunction (EF of
35% to 49%), of whom only 78 had 3-vessel CAD, the
single subgroup with improved survival with surgical
compared with medical therapy (20). Patients with
LVEF <35% were not randomized in CASS but were
reported in the CASS registry (10). In a meta-analysis
of 7 clinical trials of medical therapy versus CABG
from the 1970s and 1980s (21), only 7% of patients
(n ¼ 178) had LVEF <40%.
Unfortunately, more contemporary trials studying
treatments for CAD that included an intensive medi-
cal regimen, such as the MASS-II (Medicine, Angio-
plasty, or Surgery Study) trial and the COURAGE
(Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) trial, excluded patients
with severe LV dysfunction (22,23). The BARI
2D (Bypass Angioplasty Revascularization Investi-
gation in Type 2 Diabetes) trial included patients
with LV dysfunction but only enrolled 17.5% with
LVEF <50% (24). The ISCHEMIA (International
Study of Comparative Health Effectiveness With
Medical and Invasive Approaches) trial is currently
enrolling patients but excluding those with LVEF
<35% (25).
TRIALS OF SURGICAL VERSUS
PERCUTANEOUS REVASCULARIZATION
Several trials have compared PCI (balloon angio-
plasty, bare-metal stents, and drug-eluting stents)
and CABG in patients with multivessel CAD. Among
27 randomized controlled trials comparing these 2
revascularization strategies (26), the overwhelming
majority of patients had preserved LV systolic func-
tion (EF >50%). None speciﬁcally focused on
patients with heart failure and/or LV systolicdysfunction. Two relatively large trials that
included patients with LV dysfunction were
BARI (Bypass Angioplasty Revascularization
Investigation) (27), in which 22% of patients
had LVEF <50%, and AWESOME (Angina
With Extremely Serious Operative Mortality
Evaluation) (28), in which 21% had LVEF
<35%. Subgroup analyses in patients with LV
dysfunction from these trials suggest no
difference in outcome between PCI and
CABG (29,30), but combined these analyses
involve <500 patients and include PCI with
both balloon angioplasty and bare-metal
stents.
The most recent trials comparing PCI with
CABG failed to provide more clarity. Only
approximately 2% of patients enrolled in
the SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and
Cardiac Surgery) trial had LVEF <30%
(31). More recently, the NHLBI-sponsored
FREEDOM (Future Revascularization Evalu-
ation in Patients With Diabetes Mellitus: Optimal
Management of Multivessel Disease) trial (32) re-
ported similar outcomes with PCI with drug-eluting
stents and CABG in patients with LVEF <40%, but
only 32 patients (2.5%) were in this pre-speciﬁed
subgroup. Thus, the available data are insufﬁcient
to adequately compare PCI and CABG in patients
with severe LV dysfunction.
THE STICH TRIAL
The STICH trial is the only prospective, randomized,
controlled trial to speciﬁcally investigate the role of
CABG in patients with LVEF #35% who are also
receiving GDMT. This NHLBI-sponsored trial tested 2
hypotheses among patients with LVEF #35% and
CAD amenable to CABG (33): the surgical revascu-
larization hypothesis evaluated CABG compared
with GDMT alone (n ¼ 1,212), and the surgical ven-
tricular reconstruction hypothesis compared CABG
with and without SVR (n ¼ 1,000). Patients with
Canadian Heart Association functional class III or IV
angina and those with left main coronary artery
stenosis $50% were excluded from the surgical
revascularization arm but were eligible for the
surgical ventricular reconstruction arm. GDMT
included renin-angiotensin-aldosterone system in-
hibitors, beta-blockers, statins, and antiplatelet agents
titrated to optimal doses; diuretic agents and digitalis
were also used. If possible, surgical therapy included at
least 1 internal thoracic conduit, which was accom-
plished in 91% (34).
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618THE STICH REVASCULARIZATION HYPOTHESIS. The
1,212 patients in this arm of the trial were enrolled in
99 sites in 22 countries (34). Using a pre-speciﬁed
intention-to-treat analysis, no signiﬁcant difference
was observed in the primary outcome of all-cause
mortality between patients randomized to CABG
versus GDMT over a median follow-up period of 56
months (Figure 1A). Notably, the CABG group had
improved rates of death from cardiovascular causes
and improved rates of a combined endpoint of death
from any cause and hospitalization for heart failure,
which were pre-speciﬁed secondary endpoints
(Figures 1B and C) (34). In addition, as-treated, per-
protocol, and adjusted analyses to account forFIGURE 1 Survival Analyses in the STICH Trial Using an Intention-to
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and quality of life. Blinded endpoint adjudication
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exerted a beneﬁt across all common causes of death
among patients with HF-REF: sudden death, pump
failure death, and death from myocardial infarction
(37). We believe these ﬁndings show an overall
beneﬁt of CABG against the background of GDMT in
patients with severe ischemic LV dysfunction. As
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619in the STICH trial are continuing to be followed up
to 10 years after initial randomization (38).
THE STICH REVASCULARIZATION HYPOTHESIS:
SUBSET ANALYSES. Additional analyses of the
STICH trial have been performed to identify subsets
of patients with CAD and severe LV dysfunction most
likely to beneﬁt from revascularization. The initial
target of these analyses was myocardial viability
assessment, which was prospectively programmed
into the design of the STICH trial. Multiple observa-
tional analyses and meta-analyses suggest that
viability testing may be a powerful tool that will not
only predict improvement in LV function after CABG
but will also identify patients with CAD and HF-REF
with the greatest survival beneﬁt from CABG
compared with GDMT (39,40). These analyses are
limited by their retrospective design, heterogeneous
methodology to deﬁne viability, lack of adjustment
for key baseline variables such as age and comorbid-
ities, and the potential that selection of patients for
CABG might have been inﬂuenced in some studies
by the results of viability testing. Most importantly,
these cohort studies were performed before
the advent of modern GDMT, with very few pa-
tients receiving beta-blockers. Although the STICH
trial provides important insights, it does not deﬁni-
tively address the role of viability testing in allHF-REF patients. In the original trial design, viability
testing with single-photon emission computed to-
mography was required for study entry. However,
due to low enrollment, the protocol was revised to
make single-photon emission computed tomography
or viability testing with low-dose dobutamine echo-
cardiography optional but strongly encouraged (33).
As a result, 601 of the 1,212 patients enrolled in the
revascularization hypothesis arm underwent assess-
ment of myocardial viability. On the basis of pre-
speciﬁed deﬁnitions of the magnitude of viable LV
myocardium with imaging, patients were subdivided
into those with predominantly viable versus pre-
dominantly nonviable myocardium (41). The viability
analysis did not identify patients who would prefer-
entially beneﬁt from CABG. Not surprisingly, over a
median 5.1-year follow-up period, patients with
viable tissue represented a cohort with a lower mor-
tality of 37% versus 51% in patients without myocar-
dial viability. However, after adjustment for other
prognostic variables, myocardial viability was not
associated with improved survival, suggesting that
patient comorbidities and severity of LV remodeling
were more important determinants of survival.
Moreover, there was no signiﬁcant interaction with
respect to mortality between viability status and
assignment to CABG or GDMT (p ¼ 0.53). The lack of
signiﬁcant interaction between myocardial viability
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ment of patients with severe ischemic LV dysfunc-
tion is reﬂected in current recommendations for
revascularization in the 2013 American College of
Cardiology/American Heart Association guideline for
the management of heart failure (3), which indicates
that, in the absence of angina, CABG may be
considered for improving survival in patients with
ischemic heart disease with severe LV systolic
dysfunction (EF <35%), whether or not viable myo-
cardium is present (Class IIb, Level of Evidence: B).
Although the primary viability analysis in the STICH
trial was on the basis of a pre-determined dichoto-
mous separation of patients with viable versus
nonviable myocardium, a separate analysis in which
the viability data were analyzed as continuous vari-
ables also failed to show an association between
myocardial viability and improved survival with
CABG (41).
Further analysis of imaging data in the STICH trial
was performed to assess inducible myocardial
ischemia in 399 of 1,212 patients in whom stress im-
aging was performed using single-photon emission
computed tomography or dobutamine echocardiog-
raphy. This analysis failed to show enhanced survival
with CABG in any subgroups (42). This was unantici-
pated and ran counter to the prevailing wisdom from
observational studies and previous trials in patients
with normal LV systolic function or less severe LV
dysfunction. Similarly, circulating levels of brain
natriuretic peptide and soluble tumor necrosis factor
a receptor 1 were strongly related to survival in both
the surgical and medical cohorts but did not identify
those with a survival advantage with CABG (43).
These data suggest that the observed survival
beneﬁts of CABG in patients with severe LV
dysfunction are driven primarily by factors other than
biomarkers or objective measures of myocardial
viability and ischemia. Factors associated with higher
survival rates with CABG include functional status as
assessed by a 6-min walk and/or the Kansas City
Cardiomyopathy Questionnaire (44) and the interac-
tion of angiographic severity of CAD, severity of LV
systolic dysfunction, and severity of LV remodeling
(as assessed by end-systolic volume index) (45). Pa-
tients with preserved effort tolerance but with multi-
vessel CAD, lower EF, and higher end-systolic volume
index were most likely to beneﬁt from CABG with
respect to long-term survival (Central Illustration).
THE ROLE FOR ADJUNCTIVE SURGICAL VENTRICULAR
RECONSTRUCTION. Pathophysiological changes in LV
structure and function in patients with HF-REF
include remodeling of the left ventricle from itsnormal elliptical to a more spherical shape, resulting
in a dysfunctional, less efﬁcient ventricle and por-
tending a worse prognosis. SVR may potentially
reverse-remodel the left ventricle and restore some
of its original functional capacity (46–48). The proce-
dure involves removing or excluding akinetic or
dyskinetic segments of the anterior wall and reshap-
ing the left ventricle to restore its original elliptical
form.
Observational data in unblinded series suggested
that SVR was relatively safe, and was associated
with reduced LV volume, improved LV systolic
function, improved symptoms, and high survival
rates at 5 years (46–48). However, it was uncertain
whether SVR combined with CABG would result in
improved outcomes of patients with ischemic car-
diomyopathy compared with CABG alone, especially
when combined with GDMT. This equipoise led to
the surgical ventricular reconstruction arm of the
STICH trial, the only randomized clinical trial to
address the role of SVR in patients with HF-REF
(49). Patients were eligible if they had coronary ob-
structions amenable to surgical revascularization,
severe systolic dysfunction with LVEF #35%, and
dominant LV anterior akinesia or dyskinesia that
was amenable to SVR. A total of 1,000 patients were
randomized to CABG alone versus CABG plus SVR
against the background of GDMT. The primary
outcome was a composite of all-cause mortality and
cardiac hospitalization. Patients who underwent SVR
had signiﬁcantly lower LV volumes on short-term
follow-up, with a reduction in end-systolic volume
index of 19% versus 6% in those receiving CABG
alone. However, there was no signiﬁcant difference
between the 2 therapies for the primary outcome
with a median follow-up of 4 years. There also were
no differences between the 2 groups in terms of
secondary endpoints, including repeat hospitaliza-
tions, symptoms, or quality of life (49). SVR added
to CABG does not appear to improve quality of life
compared with CABG alone but does increase health
care costs (50).
Reconciling the difference between the observa-
tional data supporting SVR and the ﬁndings from the
STICH trial has led to intriguing discussions (51,52)
and observations. A secondary analysis examined
the inﬂuence of baseline LV volumes and LVEF on
outcomes. Counter to the original premise and
existing clinical thinking that patients with larger,
already-remodeled ventricles would beneﬁt from
CABG plus SVR instead of CABG alone, patients with
smaller baseline LV end-systolic and end-diastolic
diameters were more likely to beneﬁt, suggesting
a possible beneﬁt of SVR before extensive remodeling
CENTRAL ILLUSTRATION Revascularization in Heart Failure: Proposed Contributing Factors Inﬂuencing the Decision for
Revascularization in Patients With Severe Left Ventricular Dysfunction
Genetics, biomarkers, ischemia, viability assessment, and presence of mitral regurgitation do not have as signiﬁcant an impact on this decision as risk of sudden death
and recurrent infarction, functional capacity, multivessel coronary artery disease, and severity of left ventricular remodeling. BNP ¼ B-type natriuretic peptide; CABG ¼
coronary artery bypass graft surgery; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; LVEF ¼ left ventricular ejection fraction; LVESVI ¼ left ventricular end systolic
volume index; MI ¼ myocardial infarction; 6MWD ¼ 6-min walk distance; STNFR-1 ¼ soluble tumor necrosis factor receptor 1.
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621(53,54). The extent of myocardial viability in the
dysfunctional anterior wall does not appear to be an
important determinant of survival in patients un-
dergoing SVR (55).
THE ROLE FOR MITRAL VALVE SURGERY. Secondary
mitral regurgitation (MR) stemming from LV re-
modeling and dysfunction is a common complicatingfeature in patients with CAD and HF-REF, often
creating difﬁcult management decisions. Ischemic
MR arises from mitral annular dilation, restricted
systolic closure of the mitral valve leaflets, or both.
Restricted motion in ischemic MR is primarily attrib-
uted to LV remodeling with tethering of normal-
appearing mitral leaﬂets from apical and lateral
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622papillary muscle displacement after an infarction
and secondarily attributed to inadequate mitral
leaﬂet closure due to LV dysfunction and/or dyssyn-
chrony (56).
Ischemic MR contributes to heart failure morbidity
and is a powerful marker of poor prognosis in patients
with CAD and LV dysfunction (57–60). The presence
of even mild degrees of secondary MR (with small
regurgitant volumes that would be well tolerated in a
patient with mitral valve prolapse) identiﬁes patients
with LV dysfunction who have a higher risk of mor-
tality than those without MR (58,60,61). However, in
an individual patient, it is often difﬁcult to ascertain
whether ischemic MR is merely a marker of the
severity of LV dysfunction or is contributing to pro-
gressive LV dysfunction. Hence, whether secondary
MR should be targeted for therapy remains uncertain
(62). The results of surgery for secondary ischemic
MR are unproven and unpredictable in improving
patient outcomes and have never been tested against
medical therapy for LV dysfunction in a prospective
randomized trial.
Because ischemic MR is primarily a manifestation
of LV remodeling and systolic dysfunction, the initial
focus of therapy should be GDMT (63). The survival
and symptomatic beneﬁt of beta-blockers is associ-
ated with reverse LV remodeling, which also results
in reduced MR (64). The same effects are achieved
with appropriately selected patients with CRT (65).
Surgical intervention should be considered only after
GDMT and CRT are unsuccessful in improving
symptoms, with the understanding that current data
from nonrandomized studies indicate no beneﬁcial
effect on mortality (66,67). In addition, surgical mitral
valve repair is often not durable in ischemic MR
(68,69) due to progression of the underlying LV
dysfunction. Data from the NHLBI Cardiothoracic
Surgery Network randomized trial of surgery for se-
vere ischemic MR (69) reported greater durability
with mitral valve replacement compared with repair,
even among highly experienced surgeons. In patients
undergoing CABG, mitral valve repair or replacement
should be strongly considered in those with severe
MR (63). Regarding management of moderate MR in
patients undergoing CABG, the second randomized
trial from the Cardiothoracic Surgery Network re-
ported no differences in LV end-systolic volume in-
dex at 12 months in patients receiving CABG plusmitral valve repair compared to CABG alone (70). That
trial was not powered to address clinical outcomes.
Two previous small randomized trials of CABG versus
CABG plus mitral annuloplasty demonstrated longer
procedure times but greater symptomatic improve-
ment and reverse remodeling with concomitant
mitral repair (71,72). These 3 trials were not designed
to assess mortality, and the majority of patients had
LVEF >35%.
Percutaneous mitral valve therapies are of partic-
ular interest in patients at high risk for surgical
intervention, including those with secondary MR
related to CAD and HF-REF. Promising results have
been reported from Europe in such patients who
remain symptomatic despite GDMT and CRT (73–75).
Two ongoing randomized trials of transcatheter valve
repair versus medical management (76,77) may clarify
whether targeting the mitral valve in addition to
GDMT improves outcomes of patients with ischemic
MR.
CONCLUSIONS
The highest-risk patients with HF-REF are those with
ischemic cardiomyopathy. The cornerstone of treat-
ment is GDMT for all patients and CRT for appropri-
ately selected patients. In accordance with the results
of the STICH trial, we believe that surgical revascu-
larization offers improved survival and quality of life,
particularly in patients with more extensive multi-
vessel disease and the greatest degree of LV systolic
dysfunction and remodeling, who are also at the
greatest short-term risk of mortality with CABG. SVR
does not appear to add to the clinical beneﬁts of CABG
in patients with more severely remodeled ventricles.
Concomitant mitral valve surgery is warranted in
patients undergoing CABG with severe ischemic MR;
clinical trial data have questioned the indications for
concomitant mitral valve surgery in those with mod-
erate MR. Frank discussions with patients regarding
the balance of the short-term risks of surgery against
the potential for long-term beneﬁt are essential.
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